Alcohol use disorder can narrow a life slowly. What began as a way to unwind, sleep, cope, or feel less alone may become something harder to set down. You may be researching medication because you are tired of making promises to yourself that do not hold. Or because someone you love is worried.
VIVITROL® is one option worth understanding clearly. It is a prescription medication, not a test of willpower and not a complete recovery plan. For some people, a monthly injection may be a practical part of care. For others, it may not be medically appropriate or may not fit their goals.
At Allevate Health, we approach alcohol use disorder without shame. We provide care at ourthree locations: Princeton and Middletown Township, NJ, and Franklin, MA. We begin with the whole picture: your drinking history, medical needs, current medications, support system, and what you want to change.
What VIVITROL® Is and How It Works
VIVITROL® is the brand name for extended-release injectable naltrexone, an opioid antagonist. It is FDA-approved for alcohol dependence in patients who are able to abstain before starting treatment and are not actively drinking at the time of their first dose. The recommended dose is 380 mg given by a healthcare provider every four weeks or once monthly (U.S. Food and Drug Administration, 2025).
The monthly schedule can matter. Taking a daily pill is difficult when life is chaotic, when motivation shifts, or when privacy feels important. An injection does not remove every barrier, but it can reduce the need to remember a daily dose.
Still, medication is not meant to carry recovery alone. Alcohol use disorder is not simply a matter of craving. It can involve routines, grief, trauma, family dynamics, anxiety, sleep disruption, and the practical reality of where and how you live. We make room for all of it, whether you are meeting with us in Princeton or Middletown Township, NJ, or Franklin, MA.
What a Monthly Injection May Offer
A medication can create a little more space between an urge and an action. That space may help you use other supports more fully. It may make it easier to return to therapy, talk openly with family, attend a recovery group, or build a different evening routine.
The injection may also be useful for people who prefer a medication that is not taken daily. In a 2025 randomized trial, researchers directly comparedoral and extended-release injectable naltrexone among hospitalized adults with alcohol use disorder (Magane et al., 2025). Both groups substantially reduced heavy drinking days, with no significant difference in effectiveness between the two formulations. The researchers concluded that factors such as patient preference and insurance can help guide the choice between oral and injectable naltrexone.
Follow-through is personal. Research on naltrexone adherence after hospitalization found that ongoing engagement is shaped by several practical and clinical factors, rather than motivation alone (Bernstein et al., 2024). We take those factors seriously. Transportation, work, family responsibilities, finances, prior treatment experiences, and fear of being judged can all affect whether a plan is workable.
Some people seeking help also live with anxiety symptoms, depression, or trauma-related distress. Those concerns deserve attention in their own right. We do not reduce your experience to a diagnosis or a medication decision.
What VIVITROL® Cannot Do on Its Own
VIVITROL® cannot make a person ready before they are ready. It cannot resolve loneliness, repair a strained relationship, guarantee abstinence, or prevent every return to drinking. It also does not replace medical care for alcohol withdrawal.
Alcohol withdrawal can be dangerous for some people. If you have been drinking heavily or regularly, stopping suddenly may require medical assessment. Symptoms such as seizures, hallucinations, severe confusion, chest pain, or difficulty breathing need urgent medical attention.
Medication works best when it belongs to a broader plan. That plan might include individual therapy, peer support, family conversations, medical follow-up, or a change in environment. A study of extended-release naltrexone with case management in an emergency department setting examined how medication could be paired with ongoing support rather than treated as an isolated intervention (Murphy et al., 2023).
That distinction matters to us. We can discuss VIVITROL® as one part of alcohol use disorder treatment, while remaining attentive to the parts of your life that medication cannot reach by itself.
Safety Starts With a Careful Evaluation
VIVITROL® requires a clinical evaluation and prescription. Before considering it, we review your alcohol use, opioid use, medications, medical history, liver health, and mental health history. We also ask what has and has not helped before.
Because naltrexone blocks opioid receptors, VIVITROL® should not be started in someone who is currently receiving opioids or has current physiological opioid dependence. TheFDA prescribing information recommends an opioid-free interval of at least 7–10 days before treatment for patients previously dependent on short-acting opioids because starting VIVITROL® too soon can trigger severe withdrawal. The prescribing information also includes warnings related to liver injury and injection-site reactions. Commonly reported adverse effects in alcohol-dependence trials included nausea, headache, dizziness, fatigue or malaise, sleep disturbance, anxiety, decreased appetite, and injection-site reactions (U.S. Food and Drug Administration, 2025).
This is why an evaluation matters. We want you to understand both the possible benefits and the limits before deciding. There should be no pressure to accept a medication that does not feel medically or personally right.
If depression, trauma, or another concern is also present, our depression care and PTSD support can help you explore those needs separately and thoughtfully.
Preparing for a Conversation About VIVITROL®
You do not need perfect language for this appointment. You only need candor. During an evaluation, your clinician may ask about:
How often you drink and what a typical day looks like
When drinking feels hardest to control
Any past withdrawal symptoms
Current or recent opioid use, including prescribed pain medication
Other medications, supplements, and medical diagnoses
What you hope will be different in the next few months
Frequently Asked Questions
Does VIVITROL® cure alcohol use disorder?
No. Alcohol use disorder is a treatable health condition, but there is no single medication that cures it. VIVITROL® may be one tool within a larger plan that supports your goals.
Will VIVITROL® stop cravings completely?
Not necessarily. Some people may notice a change in cravings or drinking patterns, while others may not experience the same effect. We do not promise a particular response.
Do I have to be abstinent before receiving VIVITROL®?
Before starting VIVITROL® for alcohol dependence, theFDA prescribing information states that patients should be able to abstain from alcohol and should not be actively drinking at the time of the first dose. Your clinician will also assess your withdrawal risk and overall medical situation. Current or recent opioid use is especially important to disclose because VIVITROL® can precipitate severe opioid withdrawal if opioids are still in your system.
Can I receive VIVITROL® if I take opioid pain medication?
VIVITROL® is contraindicated in patients currently receiving opioid analgesics. Because naltrexone blocks opioid receptors, current and recent opioid use must be discussed with your clinician before treatment. Your clinician can review your medications, pain-management needs, and the appropriate opioid-free interval before determining whether VIVITROL® is an option.
Is medication enough without therapy or support?
For some people, medication is an important beginning. But we encourage a broader plan whenever possible. A systematic review of anti-craving medications in emergency care reflects the need for thoughtful clinical decision-making rather than a one-size-fits-all answer (Punia et al., 2024).
A More Honest Place to Begin
Seeking medication does not mean you have failed. It may mean you are ready to try a different kind of support. At Allevate Health, we will listen without asking you to perform certainty, optimism, or shame.
If you are considering VIVITROL® for alcohol use disorder, a consultation can help you understand whether this medication may belong in your care plan and what support around it may be most useful.
Princeton, NJ: 640-252-9785Middletown Township, NJ: 848-345-5831Franklin, MA: 774-855-5117
Medical disclaimer
The information in this blog is for educational purposes only and does not constitute medical advice. Seasonal patterns, depression, and bipolar symptoms require evaluation by a licensed provider familiar with your medical and mental health history. Individual needs and outcomes vary. If you are experiencing a mental health crisis or thoughts of self-harm, call or text 988 to reach the Suicide and Crisis Lifeline, call 911, or go to your nearest emergency room.
Works Cited
1. U.S. Food and Drug Administration. VIVITROL® (naltrexone for extended-release injectable suspension) Prescribing Information. Revised December 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021897s061lbl.pdf
2. Magane KM, Dukes KA, Fielman S, et al. Oral vs Extended-Release Injectable Naltrexone for Hospitalized Patients With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Internal Medicine. 2025;185(6):635–645. https://pubmed.ncbi.nlm.nih.gov/40257810/
3. Bernstein EY, Magane KM, Dukes KA, et al. Correlates of Post-Hospitalization Naltrexone Adherence for Alcohol Use Disorder. Drug and Alcohol Dependence. 2024;265:112470. https://pubmed.ncbi.nlm.nih.gov/39461121/
4. Murphy CE 4th, Coralic Z, Wang RC, et al. Extended-Release Naltrexone and Case Management for Treatment of Alcohol Use Disorder in the Emergency Department. Annals of Emergency Medicine. 2023;81(4):440–449. https://pubmed.ncbi.nlm.nih.gov/36328851/
5. Punia K, Scott W, Manuja K, et al. SAEM GRACE: Anti-Craving Medications for Alcohol Use Disorder Treatment in the Emergency Department: A Systematic Review of Direct Evidence. Academic Emergency Medicine. 2024;31(5):504–514. https://pubmed.ncbi.nlm.nih.gov/37735346/
Disclaimer
This article is for educational purposes only and is not a substitute for individualized evaluation, diagnosis, or treatment from a qualified healthcare professional.